「双语」例行记者会/RegularPressConference（2021-6-2）(7)

继5月7日中国国药疫苗通过审评后，中国科兴公司的疫苗再次获批，充分证明中国有关疫苗和技术路线的安全性和有效性，为全球早日战胜疫情提供了更多有力工具。 Wang Wenbin: The Sinovac vaccine is the second Chinese vaccine to win the WHO listing, after Sinopharm vaccine was granted approval on May 7. This fully attests to the safety and efficacy of relevant vaccines and technical lines that provide more powerful tools for the world to overcome the epidemic at an early date. 中方一直以实际行动践行习近平主席关于疫苗全球公共产品的宣示，积极鼓励和支持中国疫苗企业申请列入世卫组织紧急使用清单。
在自身人口基数巨大、疫苗供应十分紧张的情况下，中方已经向国际社会提供了超过3.5亿剂疫苗，包括向80多个国家提供疫苗援助，向40多个国家出口疫苗。同时，中方还同多个发展中国家开展合作生产，迅速推进疫苗大规模生产，国药集团向“新冠疫苗实施计划”供应的首批疫苗5月31日正式下线，为疫苗在发展中国家的公平可及作出了实实在在的贡献。 China has been acting on General Secretary Xi Jinping"s pledge to make COVID-19 vaccines a global public good, and has been encouraging and supporting Chinese vaccine manufacturers to apply for the WHO"s Emergency Use Listing. Despite its own huge population and tight vaccine supply, China has provided more than 350 million doses of vaccines to the international community, including vaccine assistance to over 80 countries and vaccine exports to 40 plus countries. In addition, China has also carried out production cooperation with a number of developing countries to promote large-scale production of vaccines at a fast pace. The first batch of Sinopharm vaccines to be provided to COVAX rolled off production line on May 31, representing a real contribution to enhancing the equitable distribution and accessibility of vaccines in developing countries.